房颤患者缺血性卒中前抗栓治疗与初始卒中严重程度的关系
基于全国多中心卒中登记数据,纳入6786例卒中前已知房颤的急性缺血性卒中患者,分析卒中前抗栓药物使用趋势及其与初始卒中严重程度和院内结局的关联。研究发现抗凝药使用持续增加,但近三分之一患者卒中前未接受抗栓治疗;卒中前使用抗血小板或抗凝药与更轻的初始神经功能缺损及更佳的出院结局相关。
要点
- 房颤相关急性缺血性卒中患者中近三分之一卒中前未接受抗栓治疗。
- 卒中前使用抗血小板或抗凝药者初始NIHSS评分更低、出院mRS 0-2比例更高。
- 抗血小板和抗凝药使用均与轻度初始神经功能缺损(NIHSS≤5)独立相关。
核心结论
- 研究期间房颤合并急性缺血性卒中患者抗凝药使用比例持续增加,但仍有近三分之一患者卒中前未接受抗栓治疗。
- 卒中前使用抗凝药与轻度初始神经功能缺损及出院良好结局的更高可能性显著相关。
研究设计与样本
- 收集卒中前抗栓药物使用情况(无抗栓/抗血小板/抗凝),以NIHSS评估初始卒中严重程度,以出院mRS评估院内结局。
主要发现
- 未接受抗栓治疗者初始NIHSS评分高于接受抗血小板者(中位数8 vs 7)和接受抗凝者(中位数8 vs 6),P<0.001。
- 出院良好结局(mRS 0-2)在接受抗血小板或抗凝治疗者中更常见(P<0.001)。
- 抗血小板使用与轻度初始神经功能缺损(NIHSS≤5)相关(OR 1.23,95%CI 1.09-1.38)。
- 抗凝药使用与轻度初始神经功能缺损(NIHSS≤5)相关(OR 1.31,95%CI 1.15-1.50)。
临床怎么用
- 对已知房颤患者应重视卒中前抗栓治疗评估,抗凝治疗与更轻的初始卒中严重程度和更佳出院结局相关。
- 近三分之一房颤患者卒中前未接受抗栓治疗,提示需加强房颤患者卒中预防管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is the leading cause of ischemic stroke. Preventive antithrombotic use, especially for anticoagulation, reduces the incidence of ischemic stroke in patients with AF. Using data from the nationwide multicenter stroke registry, we investigated the trends of preceding antithrombotic medication use in patients with acute ischemic stroke (AIS) with AF and its association with initial stroke severity and in-hospital outcomes. METHODS: This study included 6786 patients with AIS with known AF before stroke admission across 39 hospitals between June 2008 and December 2018. We collected the data on antithrombotic medication use (no antithrombotic/antiplatelet/anticoagulant) preceding AIS. Initial stroke severity was measured using the National Institutes of Health Stroke Scale, and in-hospital outcome was determined by modified Rankin Scale score at discharge. RESULTS: During the study period, anticoagulant use continued to increase. However, nearly one-third of patients with AIS with known AF did not receive antithrombotics before stroke. Initial National Institutes of Health Stroke Scale scores varied according to preceding antithrombotic therapy (P<0.001). It was higher in patients who did not receive antithrombotics than in those who received antiplatelets or anticoagulants (median National Institutes of Health Stroke Scale score: 8 versus 7 and 8 versus 6, respectively). Favorable outcome at discharge (modified Rankin Scale score, 0-2) was more prevalent in patients who received antiplatelets or anticoagulants (P<0.001). Use of antiplatelets (odds ratio, 1.23 [95% CI, 1.09-1.38]) and anticoagulants (odds ratio, 1.31 [95% CI, 1.15-1.50]) was associated with a mild initial neurological deficit (National Institutes of Health Stroke Scale score ≤5) in patients with AIS with AF. CONCLUSIONS: Throughout the study period, the proportion of patients taking anticoagulants increased among patients with AIS with known AF. However, a large portion of AF patients still did not receive antithrombotics before AIS. Furthermore, prehospitalization use of anticoagulants was associated with a significantly higher likelihood of a mild initial neurological deficit and favorable outcome at discharge.
引用
- Jung YH, Kim YD, Kim J, et al. Initial Stroke Severity in Patients With Atrial Fibrillation According to Antithrombotic Therapy Before Ischemic Stroke. Stroke. 2020. PMID: 32811392. doi:10.1161/STROKEAHA.120.030138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。